Microglial activation in presymptomatic Huntington's disease gene carriers.

Microglial activation may play a role in the pathogenesis of Huntington's disease (HD). Using 11C-(R)-PK11195 (PK) positron emission tomography (PET), we investigated microglial activation in HD presymptomatic gene carriers (PGCs), its relationship with striatal neuronal dysfunction measured with 11C-raclopride (RAC) PET, and the role of PK PET as a possible marker of subclinical disease progression in PGCs. Eleven HD PGCs underwent PK and RAC PET. Their results were compared with those of healthy controls. PK and RAC binding was measured using region-of-interest analysis. Regional increases in PK binding were also localized with voxel-based statistical parametric mapping. HD PGCs had lower striatal RAC binding than the controls but significantly higher striatal and cortical PK binding. Individual levels of higher striatal PK binding in PGCs correlated with lower striatal RAC binding and, after excluding one outlier, with a higher probability of developing HD in 5 years. The inverse association between striatal PK and RAC binding in PGCs continues into early to moderate stages of HD. This study demonstrated for the first time in vivo widespread microglial activation in preclinical HD which correlated with striatal neuronal dysfunction. These findings indicate that microglial activation is an early event in the pathogenic processes of HD and is associated with subclinical progression of disease. PK PET may be a useful marker of active subclinical disease and a means of investigating the efficacy of neuroprotection strategies in PGCs.

[1]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[2]  E. Yeterian,et al.  Cortico-striate projections in the rhesus monkey: The organization of certain cortico-caudate connections , 1978, Brain Research.

[3]  J. de Vellis,et al.  Microglia in health and disease , 2005, Journal of neuroscience research.

[4]  G. Bates,et al.  Minocycline and doxycycline are not beneficial in a model of Huntington's disease , 2003, Annals of neurology.

[5]  Minocycline safety and tolerability in Huntington disease , 2004, Neurology.

[6]  D J Brooks,et al.  Microglial activation correlates with severity in Huntington disease , 2006, Neurology.

[7]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[8]  T. Spinks,et al.  Physical characteristics of the ECAT EXACT3D positron tomograph. , 2000, Physics in medicine and biology.

[9]  A. Hackam,et al.  Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi , 2002, Nature Cell Biology.

[10]  A. Blamire,et al.  High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study , 2005, Neurology.

[11]  G. M. Halliday,et al.  Regional Specificity of Brain Atrophy in Huntington's Disease , 1998, Experimental Neurology.

[12]  Alexander Gerhard,et al.  In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy , 2006, Movement disorders : official journal of the Movement Disorder Society.

[13]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[14]  Nicola Pavese,et al.  Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. , 2003, Brain : a journal of neurology.

[15]  P G Bhide,et al.  Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain , 2001, Journal of neuropathology and experimental neurology.

[16]  G. Kreutzberg.  Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[17]  Guo-qiang Lu,et al.  Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration , 2005, Mechanisms of Ageing and Development.

[18]  M. Hayden,et al.  Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. , 2003, Brain : a journal of neurology.

[19]  J. Winn,et al.  Brain , 1878, The Lancet.

[20]  J. Brandt,et al.  Onset and rate of striatal atrophy in preclinical Huntington disease , 2004, Neurology.

[21]  K. Biglan,et al.  The eyes as a window into disease prevention , 2006, Neurology.

[22]  J. Koistinaho,et al.  Minocycline Provides Neuroprotection Against N-Methyl-d-aspartate Neurotoxicity by Inhibiting Microglia1 , 2001, The Journal of Immunology.

[23]  Wilhelm Gaus,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.

[24]  Jane S. Paulsen,et al.  Preparing for preventive clinical trials: the Predict-HD study. , 2006, Archives of neurology.

[25]  Jane S. Paulsen,et al.  Clinical markers of early disease in persons near onset of Huntington’s disease , 2001, Neurology.

[26]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[27]  R. Banati,et al.  Visualising microglial activation in vivo , 2002, Glia.

[28]  W. Streit.  Microglia as neuroprotective, immunocompetent cells of the CNS , 2002, Glia.

[29]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[30]  Roger N Gunn,et al.  In-vivo measurement of activated microglia in dementia , 2001, The Lancet.

[31]  J. Pruim,et al.  Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease , 2005, Neurology.

[32]  Jane S. Paulsen,et al.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.

[33]  P Boesiger,et al.  Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.